Brokerages Set Axon Enterprise, Inc (NASDAQ:AXON) Price Target at $805.71

Shares of Axon Enterprise, Inc (NASDAQ:AXON) have been assigned an average recommendation of “Moderate Buy” from the seventeen ratings firms that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $805.7143.

AXON has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. Piper Sandler lowered their target price on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. JMP Securities reiterated a “market outperform” rating and issued a $825.00 target price on shares of Axon Enterprise in a report on Monday, September 29th. UBS Group decreased their price target on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating for the company in a report on Wednesday, November 5th. Finally, Barclays lowered their price objective on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $631.73 on Friday. The firm has a fifty day moving average of $571.01 and a two-hundred day moving average of $686.17. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. The stock has a market capitalization of $49.85 billion, a price-to-earnings ratio of 199.92, a PEG ratio of 19.89 and a beta of 1.41. Axon Enterprise has a 52 week low of $469.24 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The company had revenue of $710.64 million for the quarter, compared to analyst estimates of $704.83 million. During the same period last year, the firm earned $1.45 earnings per share. The firm’s revenue for the quarter was up 30.6% on a year-over-year basis. As a group, equities research analysts predict that Axon Enterprise will post 5.8 EPS for the current year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the sale, the president directly owned 249,502 shares in the company, valued at approximately $137,874,805.20. This trade represents a 7.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $550.63, for a total transaction of $55,063.00. Following the completion of the transaction, the director directly owned 1,316 shares in the company, valued at approximately $724,629.08. The trade was a 7.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 60,540 shares of company stock valued at $34,684,738 over the last 90 days. Insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Several hedge funds have recently modified their holdings of the stock. Defender Capital LLC. bought a new position in shares of Axon Enterprise during the 4th quarter worth approximately $23,765,000. Czech National Bank lifted its holdings in Axon Enterprise by 4.4% during the 4th quarter. Czech National Bank now owns 20,807 shares of the biotechnology company’s stock valued at $11,817,000 after purchasing an additional 869 shares during the last quarter. Willner & Heller LLC bought a new position in Axon Enterprise during the fourth quarter worth $642,000. Schaper Benz & Wise Investment Counsel Inc. WI boosted its position in Axon Enterprise by 11.1% during the fourth quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 20,912 shares of the biotechnology company’s stock worth $11,877,000 after purchasing an additional 2,093 shares during the period. Finally, Avanza Fonder AB acquired a new position in shares of Axon Enterprise in the fourth quarter valued at $10,541,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.